About the Authors
- Alexander Pretsch
-
Contributed equally to this work with: Alexander Pretsch, Michael Nagl
Affiliation SeaLife Pharma GmbH, Tulln, Austria
- Michael Nagl
-
Contributed equally to this work with: Alexander Pretsch, Michael Nagl
Affiliation SeaLife Pharma GmbH, Tulln, Austria
- Katja Schwendinger
-
Affiliation SeaLife Pharma GmbH, Tulln, Austria
- Birgit Kreiseder
-
Affiliation SeaLife Pharma GmbH, Tulln, Austria
- Martina Wiederstein
-
Affiliation SeaLife Pharma GmbH, Tulln, Austria
- Dagmar Pretsch
-
Affiliation SeaLife Pharma GmbH, Tulln, Austria
- Miroslav Genov
-
Affiliation SeaLife Pharma GmbH, Tulln, Austria
- Ralph Hollaus
-
Affiliation SeaLife Pharma GmbH, Tulln, Austria
- Daniela Zinssmeister
-
Affiliation SeaLife Pharma GmbH, Tulln, Austria
- Abdesamad Debbab
-
Affiliation Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine University, Düsseldorf, Germany
- Harald Hundsberger
-
Affiliation Medical and Pharmaceutical Biotechnology, University of Applied Sciences, Krems, Austria
- Andreas Eger
-
Affiliation Medical and Pharmaceutical Biotechnology, University of Applied Sciences, Krems, Austria
- Peter Proksch
-
Affiliation Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine University, Düsseldorf, Germany
- Christoph Wiesner
-
* E-mail: wiesner@sealifepharma.com
Affiliation SeaLife Pharma GmbH, Tulln, Austria
Competing Interests
SeaLife Pharma GmbH holds the patent for the Anthracene derivatives (“Neue Tetrahydroanthracenon-Derivate”; WO 2010135758 A1; compound AA ´) isolated from T. wortmannii. A. Pretsch, P. Proksch, and A. Debbab are the inventors of the patent and SeaLife Pharma GmbH is the patent holder. In the next two years, SeaLife GmbH plans to market and commercialize the T. wortmannii extract as a cosmetic product. A. Pretsch (Head of Microbiology and CEO), M. Nagl (Head of Chemistry), K. Schwendinger (Master Student), B. Kreiseder (Junior Scientist), M. Wiederstein (Junior Scientist), D. Pretsch (Junior Scientist), D. Zinssmeister (Master Student), M. Genov (Senior Scientist), R. Hollaus (Junior Scientist), and C. Wiesner (CSO) are all employed at SeaLife Pharma GmbH. Beside the product above, SeaLife Pharma GmbH is developing (pre-clinical studies) an anti-infective Anthraquinone-Derivative (patent in preparation) for the treatment of MRSA. Up to now, SeaLife Pharma has no products on the market. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: AP CW. Performed the experiments: AP MN KS BK MW DP RH DZ HH CW. Analyzed the data: AP MG CW. Contributed reagents/materials/analysis tools: AD HH AE PP. Wrote the paper: MN CW.